- Home
- GFL vs NBIX Comparison
GFL vs NBIX Comparison
Compare GFL & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GFL | NBIX |
|---|---|---|
| Founded | 2007 | 1992 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 15.2B |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | GFL | NBIX |
|---|---|---|
| Price | $41.80 | $140.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 21 |
| Target Price | $57.18 | ★ $177.19 |
| AVG Volume (30 Days) | ★ 1.7M | 1.0M |
| Earning Date | 02-23-2026 | 02-05-2026 |
| Dividend Yield | ★ 0.14% | N/A |
| EPS Growth | N/A | ★ 12.44 |
| EPS | ★ 6.65 | 4.19 |
| Revenue | ★ $5,904,199,182.00 | $2,682,700,000.00 |
| Revenue This Year | N/A | $23.68 |
| Revenue Next Year | $7.24 | $18.47 |
| P/E Ratio | ★ $6.43 | $32.77 |
| Revenue Growth | ★ 27.49 | 19.61 |
| 52 Week Low | $41.29 | $84.23 |
| 52 Week High | $52.00 | $160.18 |
Technical Indicators
Market Signals| Indicator | GFL | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 28.74 | 42.38 |
| Support Level | $42.71 | $134.03 |
| Resistance Level | $43.90 | $148.56 |
| Average True Range (ATR) | 0.70 | 3.40 |
| MACD | -0.12 | -1.05 |
| Stochastic Oscillator | 0.57 | 38.02 |
Price Performance
Historical ComparisonAbout GFL GFL Environmental Inc. Subordinate voting shares no par value
GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. The company's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.